Teva Pharmaceutical Industries Ltd (TEVA)

$16.98

+0.17

(+1.01%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $16.83
    $17.18
    $16.98
    downward going graph

    0.88%

    Downside

    Day's Volatility :2.04%

    Upside

    1.16%

    downward going graph
  • $8.06
    $17.69
    $16.98
    downward going graph

    52.53%

    Downside

    52 Weeks Volatility :54.44%

    Upside

    4.01%

    downward going graph

Returns

PeriodTeva Pharmaceutical Industries LtdSector (Health Care)Index (Russel 2000)
3 Months
30.51%
5.3%
0.0%
6 Months
41.62%
6.3%
0.0%
1 Year
96.53%
9.2%
0.0%
3 Years
92.74%
13.1%
-19.9%

Highlights

Market Capitalization
19.0B
Book Value
$6.43
Earnings Per Share (EPS)
-0.42
PEG Ratio
1.84
Wall Street Target Price
19.71
Profit Margin
-2.99%
Operating Margin TTM
17.28%
Return On Assets TTM
4.84%
Return On Equity TTM
-9.67%
Revenue TTM
16.0B
Revenue Per Share TTM
14.28
Quarterly Revenue Growth YOY
4.3%
Gross Profit TTM
7.0B
EBITDA
4.5B
Diluted Eps TTM
-0.42
Quarterly Earnings Growth YOY
0.4
EPS Estimate Current Year
2.34
EPS Estimate Next Year
2.74
EPS Estimate Current Quarter
0.51
EPS Estimate Next Quarter
0.58

Analyst Recommendation

Sell
    0
    0%Buy
    33%Hold
    66%Sell
Based on 9 Wall street analysts offering stock ratings for Teva Pharmaceutical Industries Ltd(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
6
6
Hold
3
1
1
Sell
6
00
00

Analyst Forecast

What analysts predicted

Upside of 16.08%

Current $16.98
Target $19.71

Company Financials

FY18Y/Y Change
Revenue
18.9B
↓ 15.77%
Net Income
-2.2B
↓ 86.78%
Net Profit Margin
-11.4%
↑ 61.26%
FY19Y/Y Change
Revenue
16.9B
↓ 10.43%
Net Income
-999.0M
↓ 53.53%
Net Profit Margin
-5.92%
↑ 5.48%
FY20Y/Y Change
Revenue
16.7B
↓ 1.36%
Net Income
-4.0B
↑ 299.4%
Net Profit Margin
-23.95%
↓ 18.03%
FY21Y/Y Change
Revenue
15.9B
↓ 4.68%
Net Income
417.0M
↓ 110.45%
Net Profit Margin
2.63%
↑ 26.58%
FY22Y/Y Change
Revenue
14.9B
↓ 6.0%
Net Income
-2.4B
↓ 664.27%
Net Profit Margin
-15.77%
↓ 18.4%
FY23Y/Y Change
Revenue
15.8B
↑ 6.17%
Net Income
-559.0M
↓ 76.24%
Net Profit Margin
-3.53%
↑ 12.24%
Q4 FY22Q/Q Change
Revenue
3.9B
↑ 8.04%
Net Income
-1.2B
↓ 2280.36%
Net Profit Margin
-31.44%
↓ 33.0%
Q1 FY23Q/Q Change
Revenue
3.7B
↓ 5.74%
Net Income
-205.0M
↓ 83.21%
Net Profit Margin
-5.6%
↑ 25.84%
Q2 FY23Q/Q Change
Revenue
3.9B
↑ 5.93%
Net Income
-863.0M
↑ 320.98%
Net Profit Margin
-22.25%
↓ 16.65%
Q3 FY23Q/Q Change
Revenue
3.9B
↓ 0.72%
Net Income
80.0M
↓ 109.27%
Net Profit Margin
2.08%
↑ 24.33%
Q4 FY23Q/Q Change
Revenue
4.5B
↑ 15.77%
Net Income
429.0M
↑ 436.25%
Net Profit Margin
9.63%
↑ 7.55%
Q1 FY24Q/Q Change
Revenue
3.8B
↓ 14.02%
Net Income
-139.0M
↓ 132.4%
Net Profit Margin
-3.63%
↓ 13.26%
FY18Y/Y Change
Total Assets
60.7B
↓ 14.07%
Total Liabilities
44.9B
↓ 13.46%
FY19Y/Y Change
Total Assets
57.5B
↓ 5.29%
Total Liabilities
42.4B
↓ 5.53%
FY20Y/Y Change
Total Assets
50.6B
↓ 11.88%
Total Liabilities
39.6B
↓ 6.67%
FY21Y/Y Change
Total Assets
47.7B
↓ 5.87%
Total Liabilities
36.4B
↓ 7.98%
FY22Y/Y Change
Total Assets
44.0B
↓ 7.68%
Total Liabilities
35.3B
↓ 3.04%
FY23Y/Y Change
Total Assets
43.5B
↓ 1.2%
Total Liabilities
35.4B
↑ 0.11%
Q4 FY22Q/Q Change
Total Assets
44.0B
↓ 0.56%
Total Liabilities
35.3B
↑ 1.67%
Q1 FY23Q/Q Change
Total Assets
43.5B
↓ 1.25%
Total Liabilities
34.8B
↓ 1.33%
Q2 FY23Q/Q Change
Total Assets
43.1B
↓ 0.83%
Total Liabilities
35.4B
↑ 1.56%
Q3 FY23Q/Q Change
Total Assets
42.1B
↓ 2.34%
Total Liabilities
34.6B
↓ 2.29%
Q4 FY23Q/Q Change
Total Assets
43.5B
↑ 3.3%
Total Liabilities
35.4B
↑ 2.24%
Q1 FY24Q/Q Change
Total Assets
42.8B
↓ 1.62%
Total Liabilities
35.2B
↓ 0.35%
FY18Y/Y Change
Operating Cash Flow
2.4B
↓ 30.25%
Investing Cash Flow
1.9B
↓ 13.77%
Financing Cash Flow
-3.4B
↓ 41.72%
FY19Y/Y Change
Operating Cash Flow
538.0M
↓ 78.0%
Investing Cash Flow
1.4B
↓ 27.38%
Financing Cash Flow
-241.0M
↓ 92.81%
FY20Y/Y Change
Operating Cash Flow
1.2B
↑ 126.02%
Investing Cash Flow
863.0M
↓ 36.31%
Financing Cash Flow
-1.9B
↑ 682.16%
FY21Y/Y Change
Operating Cash Flow
798.0M
↓ 34.37%
Investing Cash Flow
1.5B
↑ 76.48%
Financing Cash Flow
-2.2B
↑ 15.23%
FY22Y/Y Change
Operating Cash Flow
1.6B
↑ 99.25%
Investing Cash Flow
656.0M
↓ 56.93%
Financing Cash Flow
-1.5B
↓ 31.54%
Q4 FY22Q/Q Change
Operating Cash Flow
973.0M
↑ 79.19%
Investing Cash Flow
168.0M
↑ 14.29%
Financing Cash Flow
-713.0M
↑ 62.05%
Q1 FY23Q/Q Change
Operating Cash Flow
-145.0M
↓ 114.9%
Investing Cash Flow
302.0M
↑ 79.76%
Financing Cash Flow
-706.0M
↓ 0.98%
Q2 FY23Q/Q Change
Operating Cash Flow
324.0M
↓ 323.45%
Investing Cash Flow
302.0M
↑ 0.0%
Financing Cash Flow
-55.0M
↓ 92.21%
Q3 FY23Q/Q Change
Operating Cash Flow
5.0M
↓ 98.46%
Investing Cash Flow
184.0M
↓ 39.07%
Financing Cash Flow
-576.0M
↑ 947.27%

Technicals Summary

Sell

Neutral

Buy

Teva Pharmaceutical Industries Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
2.97%
41.62%
96.53%
92.74%
121.09%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.73%
3.47%
45.25%
47.46%
69.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.24%
7.6%
2.41%
20.38%
20.38%
Zoetis Inc.
Zoetis Inc.
5.19%
-3.9%
-2.6%
-11.21%
55.91%
Viatris Inc.
Viatris Inc.
11.46%
-0.85%
9.89%
-16.16%
-28.58%
Catalent, Inc.
Catalent, Inc.
3.12%
18.35%
21.46%
-49.91%
6.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
30.17
NA
1.84
2.34
-0.1
0.05
NA
6.43
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.34
34.34
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Sell
$19.0B
121.09%
30.17
-2.99%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
69.5%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.38%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.5B
55.91%
34.34
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-28.58%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
6.12%
211.02
-28.44%

Insights on Teva Pharmaceutical Industries Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.45B → 3.83B (in $), with an average decrease of 14.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 429.0M → -139.0M (in $), with an average decrease of 132.4% per quarter

Institutional Holdings

  • BlackRock Inc

    3.86%
  • Ion Asset Management Ltd.

    3.41%
  • Phoenix Holdings Ltd

    3.05%
  • Migdal Insurance & Financial Holdings Ltd

    2.64%
  • Clal Insurance Enterprises Holdings Ltd

    2.54%
  • MENORA MIVTACHIM HOLDINGS LIMITED

    2.48%

Corporate Announcements

  • Teva Pharmaceutical Industries Ltd Dividends June,2017

    In the quarter ending June,2017. Teva Pharmaceutical Industries Ltd has declared dividend of $0.09

    Read More

Company Information

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Organization
Teva Pharmaceutical Industries Ltd
Employees
35001
CEO
Mr. Eliyahu Sharon Kalif
Industry
Health Technology

FAQs